- Home
- CLPR vs ICCM Comparison
CLPR vs ICCM Comparison
Compare CLPR & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLPR | ICCM |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.6M | 45.5M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLPR | ICCM |
|---|---|---|
| Price | $3.49 | $0.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 67.7K | ★ 368.6K |
| Earning Date | 11-13-2025 | 11-19-2025 |
| Dividend Yield | ★ 11.01% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $154,179,000.00 | $2,975,000.00 |
| Revenue This Year | N/A | $13.67 |
| Revenue Next Year | N/A | $38.55 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.90 | N/A |
| 52 Week Low | $3.37 | $0.59 |
| 52 Week High | $6.49 | $1.66 |
Technical Indicators
Market Signals| Indicator | CLPR | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 41.96 | 39.69 |
| Support Level | $3.38 | $0.67 |
| Resistance Level | $3.55 | $0.72 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 24.44 | 11.32 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.